[{"0":"  [**2105-2-21**]              Discharge Date:   [**2105-2-22**]  Date of Birth:  [**2029-6-1**]             Sex:   F  Service: MEDICINE  Allergies: Sulfa (Sulfonamides) \/ Penicillins \/ Tetracyclines  Attending:[**Last Name (NamePattern4) 290**] Chief Complaint: tongue swelling  Major Surgical or Invasive Procedure: None   History of Present Illness: -- per admitting resident -- Mrs. [**Known lastname **] is a 75-year-old woman with controlled metastatic renal cell carcinoma on everolimus on trial 08-034 A Study, presents with acute onset tongue swelling at 1pm today after waking up from nap. . Associated with drooling, voice change. No shortness of breath or wheezing. Took prednisone 50 mg PO and benadryl 50 mg PO prior to coming in. Similar episode on [**1-14**] after dose of aranesp. . On [**1-14**], she received a an aranesp shot in [**State 108**] - her HCT was 28.6. The following day, she woke up with a complaint of tongue swelling, difficulty swallowing which progressed over the morning. She called her oncologist who reccommended she see her local practitioner. She was started on RTC benadryl and given prednisone. . In the interim, on [**2-5**], Patient had UTI tx by Cipro after which she self dc'd oxybutynin and started pravastatin. On [**2-13**], patient had ongoing frequency and urgency. Started macrobid with good effect. On [**2-20**], Patient developed painful mouth sores = bilateral and top of tongue - had difficulty eating.  Started magic mouthwash. . In the ED, initial vs were: T 98.1 P 82 BP 127\/54 R 16 O2 sat 100. Patient was given 125 of solumedrol, 40 of famotidine, 50 of benadryl. She was noted to have laryngeal edema by direct visualization and thus admitted to the ICU. . Review of sytems: (+) Per HPI (-) Denies fever, chills, night sweats, recent weight loss or gain. Denies headache, sinus tenderness, rhinorrhea or congestion. Denied cough, shortness of breath. Denied chest pain or tightness, palpitations. Denied nausea, vomiting, diarrhea, constipation or abdominal pain. No recent change in bowel or bladder habits. No dysuria. Denied arthralgias or myalgias.  Past Medical History: HTN OA s\/p bilateral hip replacement. (R hip [**2089**], L hip [**2094**]) Metastatic renal cell CA (as above) . Oncologic History: ONCOLOGIC HISTORY: Metastatic renal cell carcinoma. - [**10\/2092**]: Diagnosed during evaluation of mildly abnormal LFTs. Left nephrectomy and bilateral salpingo-oophorectomy were performed, with pathology demonstrating clear cell carcinoma, grade III\/IV, displacing the kidney capsule with no nodular or vascular involvement. - [**2-\/2099**]:  Liver metastases discovered. - [**2099**]:  The patient completed 40 weeks on bevacizumab plus erlotinib (on protocol), which she discontinued in [**4-\/2100**] secondary to disease progression. - [**5-\/2100**]:  She began sunitinib therapy on the SU11248 trial at 50 mg daily and was shortly thereafter admitted to the hospital for fatigue, nausea, diarrhea, jaundice, and pruritus; her medication was held for four weeks with resolution of symptoms and was subsequently restarted at 37.5 mg daily. - [**12\/2101**]:  The patient experienced a fall with a pelvic fracture, managed conservatively.  The fracture site was biopsied and showed no metastatic disease. - [**2102-4-19**] CT scan:  Stable hepatic lesions with a mild decrease in size of the previously noted portacaval lymph node. - [**2102-7-17**] CT scan:  Minimal increase in overall disease burden, with a slight increase in the size of target lesions. - [**2102-10-23**] CT: Interval increase in size of target lesions. T4 vertebral body sclerosis and collapse concerning for metastases. - [**2102-10-30**] MRI: Pathologic compression fracture of T4 vertebral body without retropulsion to the canal. There is a cystic structure measuring 1.4 x 1.3 cm, immediately anterior to the compressed vertebral body, which could represent cystic node, posterior mediastinal bronchogenic or enterogenous cyst or meningocele. - [**2101-12-31**]:  Due to progressive disease and inability to tolerate sunitinib, the patient signed consent for participation in the avid 07-113 trial, on which she began 20 mg of the ABT 869 study drug.  Treatment was held on [**11-15**] due to severe nausea and vomiting with dehydration, anorexia, fatigue, and worsening of the skin ulcerations that had developed on sunitinib.  She restarted the drug at 15 mg daily, discontinuing it again on [**12-28**] secondary to worsening skin ulcerations and restarting it at 12.5 mg daily on [**2103-1-23**]. The drug was again held on [**3-13**] for skin blistering on her left heel and restarted at 10mg daily on [**2103-3-26**]. -[**2103-5-14**]: ABT 869 held due to left heel wound and restarted in [**6-28**]. -[**4-29**]: drug held due to transient loss of vision. Restarted 10 days later with permission from study.  She developed POD in [**8-29**] and discontinued the [**Doctor Last Name 360**]. -[**2104-10-7**] C1D1 Everolimus on 08-034 A Study Evaluating FDG-PET as a Predictive Marker For mTOR Directed Therapy with RAD001 in Metastatic Renal Cell Cancer  "}]